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Background: Improved maternal nutrition and glycaemic control before and during pregnancy are thought to
benefit the health of the mother, with consequent benefits for infant body composition and later obesity risk.
Maternal insulin resistance and glycaemia around conception and in early pregnancy may be key determinants of
maternal physiology and placental function, affecting fetal nutrient supply and maternal-feto-placental
communications throughout gestation, with implications for later postnatal health.
Methods/design: This double-blind randomised controlled trial will recruit up to 1800 women, aged 18–38 years,
who are planning a pregnancy in the United Kingdom (UK), Singapore and New Zealand, with a view to studying
600 pregnancies. The primary outcome is maternal glucose tolerance at 28 weeks’ gestation following an oral
glucose tolerance test. Secondary outcomes include metabolic, molecular and health-related outcomes in the
mother and offspring, notably infant body composition. Participants will be randomly allocated to receive a twice-
daily control nutritional drink, enriched with standard micronutrients, or a twice-daily intervention nutritional drink
enriched with additional micronutrients, myo-inositol and probiotics, both demonstrated previously to assist in
maintaining healthy glucose metabolism during pregnancy. Myo-inositol is a nutrient that enhances cellular glucose
uptake. The additional micronutrients seek to address deficiencies of some B-group vitamins and vitamin D that are
both common during pregnancy and that have been associated with maternal dysglycaemia, epigenetic changes
and greater offspring adiposity. Women who conceive within a year of starting the nutritional drinks will be
followed through pregnancy and studied with their infants at six time points during the first year of life. Blood,
urine/stool, hair and cheek swabs will be collected from the mothers for genetic, epigenetic, hormone, nutrient and
metabolite measurements, and assessments of the mother’s body composition, anthropometry, health, diet and
lifestyle will be made. Infants will also undergo hair, cheek swab, urine and stool sampling for similar biological
measurements; infant body composition will be assessed and feeding recorded.
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Discussion: There is an increasing focus on the need to optimise maternal nutrition starting prior to conception.
This trial will provide evidence on the potential for nutritional interventions beginning prior to conception to
promote healthy maternal and offspring outcomes.
Trial registration: ClinicalTrials.gov, identifier: NCT02509988, Universal Trial Number U1111-1171-8056. Registered
on 16 July 2015. This is an academic-led study by the EpiGen Global Research Consortium.
Keywords: Preconception, Pregnancy, Randomised trial, Nutrition, Glucose metabolism, Metabolic diseases,
Hyperglycemia, Body compositionBackground
There is now considerable concern about the mainten-
ance of healthy glucose metabolism during pregnancy.
This has arisen by extrapolation from the increasing
number of women who develop type-2 diabetes during
their reproductive years [1, 2]. Epidemiological studies
show that children born to mothers with type-1 or type-
2 diabetes also have a greater susceptibility to diabetes
and obesity in later life [3, 4]. That this risk is related to
intrauterine exposure to hyperglycaemia is shown by the
observation that, among siblings, the risk of diabetes is
higher in those born after the mother was diagnosed
with diabetes [5]. These observations have been ex-
tended recently, as offspring exposed to even mild
hyperglycaemia during pregnancy have increased adipos-
ity and are at increased risk of later diabetes and cardio-
metabolic disease [6, 7]. Through transgenerational
perpetuation of the cycle of ‘diabetes begetting diabetes’,
these factors are driving further escalation of the epi-
demic of noncommunicable diseases [8, 9].
The rising levels of maternal adiposity and obesity are
of particular concern in both developed populations and
those undergoing rapid socioeconomic transitions [1, 10,
11]. Maternal obesity is associated with increased risk of
short-term adverse pregnancy outcomes as well as
longer-term impact on offspring health [12], which have
been postulated to be partly mediated by greater mater-
nal insulin resistance and higher glycaemia. Both with
and without clinically recognised pregnancy complica-
tions, evidence shows that a child of a mother with
higher glycaemia per se may suffer from exposure to a
suboptimal environment in utero, reducing the likeli-
hood of a healthy body composition in the offspring and
predisposing to increased childhood adiposity [13, 14].
Feeding pregnant rodents a high-fat diet gives rise to
maternal obesity and hyperglycaemia, and offspring who
become overweight demonstrate abnormalities similar to
the human metabolic syndrome; these are associated
with epigenetic changes such as altered deoxyribonucleic
acid (DNA) methylation at specific genetic loci impli-
cated in metabolic functions [15].
Pregnancy represents a state of relative maternal insu-
lin resistance, which helps to promote the transfer ofnutrients, such as glucose, fatty acids and amino acids,
to the fetus [16]. Placental nutrient transfer is deter-
mined by the concentration gradient, blood flow and the
operation of active and facilitated transporters [17].
However, in contrast to amino acids, there is no upper
limit to placental transfer of glucose and consequent
fetal adipose accretion as maternal blood glucose levels
rise [13]; this may be viewed as adaptive, as, in the neo-
natal period, relative adiposity provides metabolic re-
serves for thermogenesis and critical organs in the event
of inadequate maternal care [18]. However, excessive
materno-placental glucose transfer is associated with
fetal hyperinsulinemia and macrosomia [19, 20] and an
increased risk of fatal obstructed labour, suggesting that
the levels of glucose exposure of the fetus that are often
now experienced are novel in evolutionary terms [21].
Gestational diabetes mellitus (GDM) can be envisaged
as the more extreme outcome of physiological processes,
when maternal insulin resistance is accentuated by the
woman’s own developmental, genetic and environmental
circumstances: for example, women who themselves had
a lower birth weight [22] or carry genetic variants asso-
ciated with type-2 diabetes [23, 24] are at increased risk
of GDM. Established risk factors for developing GDM
include prepregnancy obesity [25], excessive gestational
weight gain [26], advanced maternal age [27] and a pre-
vious pregnancy with GDM [28]. These factors are now
increasingly common in women during their reproduct-
ive years with the evolutionary mismatched situation of
over-nutrition and low levels of physical activity contrib-
uting not only to the rise in GDM but to the increasing
prevalence of obesity and diabetes in their children, per-
petuating a vicious cycle of disease. Such changes in
growth potential and metabolic status may be mediated
by inheritable epigenetic alterations occurring in utero
[29]. For example, in Canadian first nation peoples, up
to 30% of the incidence of type-2 diabetes has its origin
in GDM in the previous generation [30]. Higher blood
glucose levels in pregnancy carry risk of cardiovascular
disease for both the mother as well as the child, a risk
which increases with each pregnancy [31].
These findings have significant long-term implications
for global public health. Now more than ever, effective
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tabolism in pregnancy are needed. Such strategies would
benefit both the mother in terms of a healthy pregnancy
and her own metabolic health, and the offspring in
terms of promoting healthy body composition and
wellbeing.
There are now data indicating that deficiency or low
levels of certain micronutrients (vitamins B6, B12 and D,
riboflavin) is extremely prevalent in pregnant women
and has lasting effects on the offspring’s risk of obesity,
acting through epigenetic processes [32–34]. Evidence
from South Asian pregnant women supports a role for
the combination of maternal vitamin B12 deficiency and
folate sufficiency in promoting offspring adiposity, most
likely mediated through impaired maternal glucose toler-
ance during pregnancy [35, 36]. Meta-analysis of obser-
vational studies strongly points to a role for maternal
vitamin D deficiency in GDM [37], and additional vita-
min D in pregnant women with GDM has been shown
to have beneficial effects on glycaemia and total and
low-density lipoprotein cholesterol (LDL)-cholesterol
concentrations [38]. Low zinc intake and status has also
been linked with maternal glycaemia [39], and we
propose that maternal glucose tolerance may be on the
causal pathway linking maternal micronutrient defi-
ciency to offspring adiposity. Importantly, among the
pregnant women who we studied in Southampton and
Singapore there was a low prevalence of deficiency in
folate and iron, the two most common micronutrients
currently targeted for supplementation in pregnancy,
and neither was associated with altered epigenetic adi-
posity biomarkers or with the child’s adiposity.
Dietary myo-inositol is found in free form but can also
be generated by microbial action in the gastrointestinal
tract from food sources of phosphatidylinositol and phy-
tic acid and its salts [40]. Myo-inositol is considered
nonessential for mammals because it is synthesised de
novo from glucose-6-phosphate in the kidney and other
tissues [41, 42]. Abnormalities in its metabolism have
been associated with insulin-resistance and its depletion
has been frequently observed in tissues affected by dia-
betic microvascular and neurological complications in
animal models and human subjects [43]. Our current
understanding of the molecular pathways of insulin ac-
tion led to the hypothesis that the nutritionally derived
myo-inositol may increase insulin sensitivity by making
available more phosphatidylinositol and potentially in-
ositol glycan secondary messengers [44, 45]. An increas-
ing number of publications suggest that myo-inositol
may reduce insulin resistance during pregnancy [46–49].
Recent studies suggest that specific bacteria may posi-
tively influence cardiometabolic parameters, possibly
through their interaction with the host and the effect of
microbial-derived metabolites. There is now substantialevidence implicating a role for the gut microbiome in af-
fecting glucose metabolism [50], and probiotics may
modulate glucose tolerance through balancing gut
microbiota, normalising increased intestinal permeability
and lowering systemic and local low-grade inflammation
[51]. There is preliminary evidence that a combination
of probiotic strains during pregnancy may promote the
maintenance of healthy glucose metabolism during preg-
nancy [52].
Taken together, there is strong support for new inter-
vention studies commencing before pregnancy to pro-
vide myo-inositol and probiotics, and to improve
maternal vitamin B6, vitamin B12, vitamin D and zinc
status, aimed at optimising maternal glycaemia and glu-
cose supply to the feto-placental unit to promote healthy
offspring growth and body composition.
Aim
This double-blind randomised controlled trial in groups
of women from different ethnic groups in the UK,
Singapore and New Zealand is designed to examine the
hypothesis that, compared with standard supplementa-
tion, a nutritional drink that contains myo-inositol, pro-
biotics and additional micronutrients, commencing
before conception and continuing during pregnancy, will
assist in the maintenance of healthy glucose metabolism
in the mother and promote offspring health.
Methods/design
Trial design
Increasing evidence points to the preconception period
and early pregnancy as a critical time when impaired
maternal glucose tolerance may lead to biological alter-
ations in the placenta and fetus that result in increased
postnatal adiposity in the offspring [53]. As a conse-
quence of this important evidence, our trial uniquely will
focus on recruitment before conception and intervention
both before and during pregnancy. Substantial experi-
mental evidence from animal studies indicates that pre-
conception is a critical period in the lifecourse for
interventions to reduce later risk of metabolic dysregula-
tion in the offspring. In humans, large cohort studies
have demonstrated that preconception is a time when
factors contributing to later ill-health begin to operate,
as poor maternal and paternal diet and smoking before
conception impact on development and long-term
health of the offspring; to date, however, there are no
population-based trials of preconception nutrition in de-
veloped communities.
The flow of the trial is shown in the Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
Figure (Fig. 1). See Additional file 1 for the SPIRIT check-
list. Extensive biosampling and detailed phenotyping are
embedded in the study with longitudinal assessments at
Fig. 1 (See legend on next page.)
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Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure: trial schema. Abbreviations: PCV preconception visit, PC
preconception, PGV pregnancy visit, PDV post-delivery visit, BIA bioelectrical impedance analysis, BP blood pressure, DM diabetes mellitus, DXA dual-energy
X-ray absorptiometry, GDM gestational diabetes, HIV, human immunodeficiency virus, IFG impaired fasting glucose, IGT impaired glucose tolerance, NGT
normal glucose tolerance, OGTT oral glucose tolerance test, USS, ultrasound scan. Questionnaires: BEBQ baby eating behaviour, BM breast milk, FH family
history, GH general health, IFH infant feeding and health, IIF intentions for infant feeding, L lifestyle, M mood (Edinburgh Postnatal Depression Scale,
State-Trait Anxiety Inventory), MH medical history, MSH menstrual history, MTH maternal health, N nutrition/diet, OH obstetric history, PA physical activity, S
sleep. Biosampling: # = blood, ♥= breast milk, $ = buccal swabs, * = epithelial swabs, @ = hair, ^ = stool, ~ = urine
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throughout pregnancy and into the first year post delivery.
The biosampling and phenotyping will enable detailed
mechanistic insights and characterisation of potential new
interventions for investigation in future studies. Following
informed consent at the first preconception visit, a baseline
standard 75-g oral glucose tolerance test (OGTT) will be
conducted, nutritional status, lifestyle, mood, body anthro-
pometry and metabolic phenotype ascertained and biosam-
pling undertaken, followed by randomisation to the
intervention or control drink. At the second preconception
visit a month later, further biosampling will be undertaken
and body composition assessed by DXA (dual-energy X-ray
absorptiometry) scanning. Regular in-person and phone
contact will be made with participants to resupply control/
intervention drinks, and to encourage retention and com-
pliance during the preconception phase. Participants who
become pregnant within a year of commencing the inter-
vention or control drink will be seen around 7, 12, 20, 28
and 34 weeks of pregnancy for further phenotyping, bio-
sampling and ultrasound scans assessing fetal growth and
development. At 28 weeks’ gestation, a standard 75-g
OGTT will be repeated to ascertain the primary outcome.
Normal antenatal care will be permitted during the trial.
The fathers will be interviewed to ascertain paternal life-
style and mood, their anthropometry measured and pater-
nal biosamples collected. At birth, offspring cord blood,
umbilical cord and placental samples will be collected.
Neonatal body composition is assessed by anthropometry,
air displacement plethysmography (PEA POD) and, in a
subsample, by DXA scanning. Both breast- and formula-
fed infants will be followed up when the infant is aged 1, 3
and 6 weeks, and 3, 6 and 12 months; infant feeding will be
assessed in detail, biosamples collected and growth and
wellbeing ascertained. Breast milk samples will be collected
from a subset of participants in early infancy for nutrient
and metabolic analysis. A maternal OGTT will be repeated
again at 6 months postpartum and repeat biosamples col-
lected. The site visits will be completed at the research and
hospital facilities of the three sites in Auckland (University
of Auckland, Auckland, Waitemata and Counties Manukau
District Health Boards and Clinics, New Zealand),
Singapore (National University Hospital and National
University Health System Investigational MedicineUnit) and Southampton (National Institute for Health
Research Wellcome Trust Southampton Clinical Research
Facility and Princess Anne Hospital, University Hospital
Southampton, UK).
Recruitment
Recruitment will be via self-referral of interested women
who hear about the study via one or more of the follow-
ing: (1) local site advertisements in social (e.g. Facebook)
and general (e.g. radio, local newspapers, magazines,
posters) media, (2) information brochures given to
women engaging in community groups such as religious,
culture-based or special-interest groups, (3) information
brochures given to women identified through or at-
tending primary medical care, family planning or hos-
pital clinics (for this group, eligible women may be
contacted by a research nurse if they give permission
to the clinic to pass on their contact details for this
purpose).
Inclusion criteria are women who meet the following:
 Aged 18–38 years
 Living in Southampton, Singapore or Auckland
 In Southampton and Auckland, planning to have
future maternity care in Southampton and
Auckland, respectively
 In Singapore, willing to deliver at the National
University Hospital
 Women planning to conceive within 6 months (but
conception up to 12 months after phenotyping will
still be included)
 In Singapore only women of Chinese, Malay and
Indian ethnicity, or of mixed Chinese/Malay/Indian
ethnicity will be included
 Able to provide written, informed consent
Exclusion criteria are:
 Pregnant or lactating at recruitment (women who
are currently breastfeeding will be excluded, but no
washout period from the end of breastfeeding will
be required before study start)
 Assisted fertility apart from those taking clomiphene
or letrozole alone
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(fasting plasma glucose concentration ≥7.0 mmol/L
or post OGTT 2-h plasma glucose concentration
≥11.1 mmol/L)
 Oral or implanted contraception currently or in the
last month, or with an intrauterine contraceptive
device in situ
 Metformin or systemic steroids currently or in the
last month
 Anticonvulsant medication currently or in the last
month
 Treatment for HIV, Hepatitis B or C currently or in
the last month
 Known serious food allergy
Withdrawal criteria are:
 The participant wishes to discontinue participation
in the study
 The participant is unwilling or unable to comply
with the protocol (including attendance at study
visits, having study measures and biosampling)
 An overall uptake level of intervention/control
nutritional drink of less than 60% evidenced by
sachet counting
 The participant is pregnant before or at
preconception visit 2
 The participant suffers a miscarriage (pregnancy loss
before 24 weeks’ gestation) or ectopic pregnancy. If
the participant suffers a first-trimester pregnancy
loss and wishes to re-join the study, she will be re-
characterised as at the first baseline visit a month or
more after a negative pregnancy test and will be
assigned the nutritional drink with the same ran-
domisation code as before
 The participant presents with a multiple pregnancy
(twins or other multiples)
 The infant dies in the perinatal period (for post-
birth secondary outcomes)
 The participant suffers an adverse reaction which is
deemed by the investigator to be causally related to
the intervention
 The participant is withdrawn at the discretion of the
investigator for medical reasons
For participants who withdraw during the pregnancy
phase of the study, consent will be obtained to follow up
on key outcome measures from their medical records to
enable comparison of the characteristics of withdrawn
and studied participants.
Randomisation procedure
At preconception clinic visit 1 all eligible participants
will be randomised via the electronic study database toeither the nutritional drink or the control drink. This
database will assign each participant the appropriate
code number that is consistent with either the interven-
tion nutritional drink arm or the control drink arm.
Randomisation will be stratified by site to ensure bal-
anced allocation of participants across the two arms at
each of the three sites, with further stratification by eth-
nicity. Investigational products will be blinded by the
manufacturer with nonspeaking codes that do not allow
deduction of the identity of intervention or control
drinks. Investigators, staff performing the assessments
and data analysts will remain blind to the identity of the
allocation from the time of randomisation until either
the participant is unblinded or database lock of the pri-
mary outcome occurs. If emergency unblinding is neces-
sary, the process for this will be documented in the
study Safety Monitoring Plan.The intervention
The Nutritional Intervention Preconception and During
Pregnancy to Maintain Healthy Glucose Metabolism and
Offspring Health (NiPPeR) intervention comprises: (1) a
micronutrient-enriched nutritional drink containing
myo-inositol, vitamin D, riboflavin, vitamin B6, vitamin
B12 and zinc together with standard folic acid, iodine,
calcium, β-carotene and iron; the quantities proposed
are either standard amounts (myo-inositol [54]), en-
hanced amounts that are available in over-the-counter
products (vitamins B6, B12, riboflavin), recommended
daily allowance amounts in UK for pregnant women
(vitamin D, zinc, folic acid, iodine) or minimal amounts
for micronutrients linked with potential detrimental ef-
fects at higher doses (iron, β-carotene, calcium) and (2)
probiotics (containing Lactobacillus rhamnosus NCC
4007 (CGMCC 1.3724) also known as LPR and Bifido-
bacterium animalis sp. lactis NCC 2818 (CNCM I-3446)
also known as Bl818) [52]. The intervention group will
be compared with a control group who receive a drink
containing standard amounts of micronutrients that are
part of routine pregnancy care (including folic acid, β-
carotene, iron, calcium and iodine). The intervention is
formulated as a powder in sachets to be made up in
water immediately prior to consumption, with similar
sensory characteristics for both the intervention and
control drinks. The constituents of the intervention and
control drinks are shown in Table 1, including the ra-
tionale for the amounts included. This trial uses estab-
lished nutritional elements for which tolerability is well
established. Confirmation that the trial is not a Clinical
Trial of an Investigational Medicinal Product has been
secured from MedSafe (New Zealand), Medicines and
Healthcare products Regulatory Agency, MHRA (UK)
and the Health Sciences Authority (Singapore).




Myo-inositol 4 g Improves glucose metabolism and preliminary data suggest may maintain healthy glucose
metabolism in pregnancy; dose safely used in pregnancy
Vitamin D3 400 IU Deficiency highly prevalent and linked with glucose metabolism in pregnancy and offspring
postnatal adiposity gain; dose sufficient to reduce insufficiency while avoiding potential
concerns re adverse effects at high doses. Omission from control group supported by a
Lancet study [56]
Vitamin B6 2.6 mg Deficiency highly prevalent and linked with glucose metabolism in pregnancy and offspring
postnatal adiposity gain [33]; dose sufficient to rectify deficiency and present in current over-
the-counter products (e.g. Elevit). Omission from control group supported by usual clinical
practice
Vitamin B12 5.2 μg Deficiency highly prevalent and linked with glucose metabolism in pregnancy and offspring
postnatal adiposity gain; dose sufficient to rectify deficiency and less than that in current
over-the-counter products (e.g. Elevit). Omission from control group supported by usual clin-
ical practice
Riboflavin 1.8 mg Low intake highly prevalent and linked with offspring postnatal adiposity gain [34]; dose
sufficient to rectify deficiency and present in current over-the-counter products (e.g. Elevit).
Omission from control group supported by usual clinical practice
Zinc 10 mg Deficiency highly prevalent and linked with offspring postnatal adiposity gain [unpublished];
dose sufficient to rectify deficiency and present in current over-the-counter products (e.g. Ele-
vit). Omission from control group supported by usual clinical practice
β-carotene 720 μg (15% of vitamin A
requirements, as retinol equivalents)
Required in pregnancy in some jurisdictions
Folic acid 400 μg Standard preconception recommendation
Iron 12 mg Iron is routinely prescribed and taken before/during pregnancy, though without convincing
evidence of benefit; low dose included to lessen likelihood of additionally receiving a high-
dose iron product, which has been linked with glucose metabolism in pregnancy
Calcium 150 mg A low dose of calcium is commonly taken before/during pregnancy; provision of this will
lessen the likelihood of additional products being taken
Iodine 150 μg Standard preconception recommendation
Probiotic Taking a combination of two probiotics has been linked with maintenance of healthy glucose
metabolism in pregnancy. Probiotic capsule containing >1 × 109 cfu each of Lactobacillus
rhamnosus NCC 4007 (CGMCC 1.3724) also known as LPR and Bifidobacterium animalis sp.
lactis NCC 2818 (CNCM I-3446) also known as Bl818
Control group
Folic acid 400 μg Standard preconception recommendation
Iron 12 mg Iron is routinely prescribed and taken before/during pregnancy, though without convincing
evidence of benefit; low dose included to lessen likelihood of additionally receiving a high-
dose iron product, which has been linked with glucose metabolism in pregnancy
Calcium 150 mg A low dose of calcium is commonly taken before/during pregnancy; provision of this will
lessen the likelihood of additional products being taken
Iodine 150 μg Standard preconception recommendation http://www.cdc.gov/preconception/documents/
clinical-content_womensnutritionfactsheet3.pdf
β-carotene 720 μg (15% of vitamin A
requirements, as retinol equivalents)
Required in pregnancy in some jurisdictions
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The primary analysis will adjust for site, ethnicity and
preconception glycaemia to account for potential imbal-
ance between treatment arms amongst pregnancies
which reach 28 weeks’ gestation, examining for differ-
ences in means between the control and intervention
groups for the primary endpoint, specifically the fasting
and/or 60-min and/or 2-h glucose concentrations fol-
lowing a 75-g OGTT at 28 weeks’ gestation. Maternalglucose metabolism at 28 weeks’ gestation has been
chosen as the primary outcome as there is evidence that
maintaining normal carbohydrate metabolism during
pregnancy is associated with a healthier body compos-
ition, a reduced risk of obesity and potentially promotion
of allergic/respiratory health in the children [55], along-
side the recognised pregnancy benefits for the mother.
Secondary maternal outcomes of the initial phase of
the NiPPeR study are:
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normal duration of gestation (at least 37 weeks’
gestation), absence of GDM (defined using the
International Association of the Diabetes and
Pregnancy Study Groups criteria: glucose cut-off
values of ≥5.1 mmol/L for fasting plasma glucose,
and/or ≥10.0 mmol/L for 1-h and/or ≥8.5 mmol/L
for 2-h post load), change in fasting glucose and
OGTT glucose area under the curve from precon-
ception baseline to 28 weeks’ gestation, maternal
wellbeing/mood, absence of excessive nausea and
vomiting, adequate pregnancy weight gain (Institute
of Medicine criteria) and vaginal delivery rates
2. Reduction in maternal micronutrient insufficiency,
specifically less riboflavin, vitamin B6, vitamin B12,
zinc and vitamin D insufficiency, before and during
pregnancy
3. Alteration in gut microbiota consistent with
enhanced wellbeing
4. Alteration in maternal metabolomic and epigenetic
biomarkers consistent with improved maternal and/
or offspring wellbeing
5. Enhancement of breast milk micronutrient content,
altered immunological factors, epigenetic and
metabolomic profiles (subsample) and maintenance
of healthy lactogenesis
Secondary offspring outcomes of the initial phase of
the NiPPeR study are:
1. Neonatal adiposity measured by PEA POD
2. Birthweight 2500–4000 g, size for gestational age at
birth and customised birthweight centile
3. Reduced adiposity gain during infancy, analysed
taking account of infant feeding
4. Reduction in cord blood C-peptide as a marker of
overall glycaemia during gestation
5. Promotion of offspring wellbeing and healthy
cardiometabolic risk factors, including visceral
adiposity and markers of insulin resistance, during
infancy
6. Alteration in offspring metabolomic and epigenetic
biomarkers in perinatal samples, consistent with
improved infant metabolic and allergic wellbeing
7. Alteration in gut microbiota to a microbiota
associated with infant metabolic and allergic
wellbeing
Data and biosample collection
Study data will be collected by trained research staff
using an access-controlled, web-based database (MedS-
ciNet, Stockholm) managed with support from the data
management staff of the MRC Lifecourse Epidemiology
Unit and the Singapore Institute for Clinical Sciences.The study database will not hold personal information,
which will be stored separately at each institution with
access limited to study coordinators. Data from the web-
based database will be downloaded via a dedicated com-
puter and stored securely on the MRC Lifecourse Epi-
demiology Unit’s servers in the UK. Data extracts will be
provided for analysis by the study researchers treating
data from all three sites as a single study. All data will
be kept in accordance with the UK Data Protection Act,
and applicable regulations and guidance of each country
and institution.
Biological samples will be collected and processed
using standardised consumables, equipment and proto-
cols across the three sites and will be being stored in ac-
cordance with the UK Human Tissue Act or equivalent
at each institution in appropriately regulated biobanks.
The study database allows management of the samples.
All analysis will be carried out on anonymised data and
samples. Accredited laboratories will be used for meas-
urement of the primary outcome of plasma glucose
concentrations.Study management and governance
This double-blind randomised controlled trial is led by
investigators from the EpiGen Global Research Consor-
tium, an academic research consortium comprising rep-
resentatives from the University of Southampton (MRC
Lifecourse Epidemiology Unit and Institute of Devel-
opmental Sciences), University of Auckland (Liggins
Institute), the Growth, Development, and Metabolism
Programme of the Singapore Institute for Clinical Sciences
(an operating unit of A*STAR) and the National University
of Singapore (Translational and Clinical Research Flagship
Programme, ‘Developmental pathways to metabolic
disease’), together with the Singapore National University
Health System. Scientists from the Nestlé Research
Centre (Nestec) provided advice on aspects of the
intervention formulation, study design and specific la-
boratory analyses.
The UK sponsor of the project is the University of
Southampton; the New Zealand sponsor of the project is
Auckland UniServices Limited; the Singapore sponsor of
the project is the National University Hospital Singapore.
The sponsors are indemnified for any harms arising from
trial participation and will approve protocol amendments
for which ethics approval has been secured, alongside
update of trial registry entries. Trial oversight will be pro-
vided by an Independent Data Monitoring and Safety
Committee. The day-to-day running of the study will be
through the Trial Management Group, consisting of the
principal investigators and the clinical trial operations
director, who will be responsible for all decisions on
the study management and delivery.
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by an external, independent monitor at each site, follow-
ing the risk-based monitoring plan established for the
study, overseen by the study sponsor. Safety reporting
will be in accordance with the study Safety Monitoring
Plan and all events will be recorded in the study data-
base. An Independent Data Monitoring and Safety Com-
mittee has been established for the trial. This committee
is independent from the sponsor and competing inter-
ests and will meet annually and oversee all ethical and
safety issues in accordance with current regulations and
MRC guidelines for Data Monitoring Committees. The
Committee Charter is available from the clinical trial op-
erations director, who will coordinate and review activity
across sites.
Statistical analysis
The primary analysis will be according to the intention-
to-treat principle. Additionally, a priori sensitivity ana-
lyses will be undertaken, omitting participants with-
drawn as a consequence of reluctance to continue with
the trial, conception after taking the nutritional drink for
less than 21 days, less than 60% uptake with the inter-
vention (evidenced by sachet counting), not conceiving
after 12 months of participation or not achieving a preg-
nancy of more than 28 weeks. Further sensitivity ana-
lyses using a ‘per protocol’ or an ‘as treated’ analysis will
be performed if deemed appropriate by the trial statisti-
cians. For analysis of the primary endpoint only: if ex-
ploratory analysis reveals the presence of outliers, as
identified by independent experts and/or the trial statis-
ticians, sensitivity analysis will be performed excluding
these outliers. Analyses will be specified in the study
statistical analysis plan finalised by the Trial Manage-
ment Group before unblinding the data. The influence
of missing data will be examined using multiple imput-
ation techniques. There are no formal planned interim
analyses of the primary outcome, but progress reports
on all data issues will be presented to the Independent
Data Monitoring and Safety Committee, who will agree
their charter at their first meeting. Analyses of the base-
line phenotypic data that do not require unblinding will
be undertaken. We will build prognostic models using
baseline covariates on the primary outcome of maternal
glucose tolerance in pregnancy. Planned subgroup ana-
lyses will include stratification by ethnicity across study
sites.
Power calculations
By studying up to 900 prepregnant participants in each
of the intervention and control groups, a total of 600
pregnancies and 500 live births is conservatively antici-
pated, following attrition from miscarriage, ectopic preg-
nancy, perinatal demise, multiple pregnancy, voluntaryparticipant withdrawal, inability to comply with the
protocol, withdrawal for medical reasons at the discre-
tion of the investigator and loss-to-follow-up. A study of
250 pregnancies with 28-week OGTT data in each group
has 89% power to detect a 0.1-mmol/L reduction in fast-
ing plasma glucose and 84% power to detect a 0.3-
mmol/L reduction in 2-h plasma glucose at the 5% level
of significance. In the Hyperglycemia and Adverse Preg-
nancy Outcomes (HAPO) study such changes in glucose
concentrations were associated with >10% changes in
the odds of macrosomia and sum of neonatal skinfolds
>90th centile and with a >20% change in cord C-peptide
>90th centile [6]. As a further illustration of statistical
power, using the distribution of 60-min plasma glucose
in the HAPO study, a study of 250 participants in each
of the two groups has 80% power to detect a difference
of ≥0.43 mmol/L in 60-min glucose at P < 0.05. A study
of 300 pregnancies in each arm will have an 80% power
to detect a reduction in the mean plasma glucose of
0.12, 0.45 and 0.34 mmol/L at fasting, 60 min and 2 h,
respectively, with an alpha of 0.017 taking into account
multiple testing.
Discussion
This double-blind randomised controlled trial in groups
of women from different ethnic groups in the UK,
Singapore and New Zealand is designed to examine the
hypothesis that a nutritional drink, commencing before
conception and continuing during pregnancy, will assist
in the maintenance of healthy glucose metabolism in the
mother and promote offspring health. Improved mater-
nal nutrition and glycaemic control before and during
pregnancy has benefits for the health of the mother and
her offspring, including healthy offspring body compos-
ition and decreased risks of childhood obesity and aller-
gies. The intervention group will receive a nutritional
drink enriched with micronutrients, myo-inositol and
probiotics, and the control group will receive a drink
enriched with standard micronutrients. The potential for
adverse effects of the intervention is low as the probiotic
and myo-inositol are thought to exert their main effects
through physiological modulation of maternal metabol-
ism rather than through direct effects on the fetus and,
while the amounts of micronutrients in the nutritional
drink are sufficient to rectify maternal deficiency, they
do not exceed UK, Singapore and New Zealand safe
upper limits.
The trial commences preconception as studies by
Catalano et al. [53] suggest that a major part of the risk of
macrosomia originates in early pregnancy/prepregnancy
and adverse pregnancy outcomes are associated with poor
maternal nutrition at conception; maternal insulin resist-
ance and hyperglycaemia in the very earliest stages of
pregnancy alter placental anatomy and physiology in ways
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and fetal fat accretion, as well as bilateral maternal-feto-
placental cross-talk, with consequences for later postnatal
health. As a consequence, intervention commencing in
established pregnancy can only partially influence fetal
growth and development. The earlier that maternal gly-
caemia is optimised and micronutrient deficiencies pre-
vented, the greater the likelihood of maintaining fetal and
postnatal health and wellbeing. Many influential govern-
mental and nongovernmental organisations are now stres-
sing the importance of optimising preconception nutrition
in general terms but as yet, other than folic acid to prevent
neural tube defects, there are few preconception interven-
tions that are recognised as promoting health benefits for
the mother or offspring, and none, apart from folic acid,
has a robust evidence base.
In the initial phase of the NiPPeR study a broad range
of maternal nutritional assessments, potential epigenetic
mechanisms and secondary measures relating to preg-
nancy outcomes and infant growth, body composition
and wellbeing will be characterised and are detailed in
this protocol.
The extensive biosampling and detailed phenotyping
embedded in the study before, during and after preg-
nancy will provide an important discovery pipeline for
the development of novel biomarkers of maternal and
offspring wellbeing, and lead to new interventions and
future guidelines to promote healthy human growth and
development. A range of biological samples collected at
multiple time points before, during and after pregnancy
in the mother and offspring enables a systems biology
approach to understanding the complex interaction of
factors that determine maternal and infant wellbeing.
Both individually and collectively, the control and inter-
vention arms will provide extensive information that will
deliver new knowledge on how maternal nutrition and
metabolic state can promote offspring health. The re-
search will also benefit from insights arising from other
studies by the EpiGen Global Research Consortium in
the UK, Singapore and New Zealand. The ethnicities of
the participants in the study will allow broad extrapola-
tion of the findings, and enable subsequent smaller-scale
studies in other jurisdictions, such as China and India,
as appropriate. The partners have extensive experience
of following up prospective mother-offspring cohorts,
maternal, obstetrical, fetal and infant medicine and
health care, and detailed characterisation of a com-
prehensive set of health and wellbeing outcomes
through infancy and childhood will be undertaken.
The data collected will allow determination of the
contributions of nutritional and lifestyle factors, socioeco-
nomic status, ethnicity, genetics, transcriptomics, epige-
nomics, metabolomics and metagenomics to maintaining
healthy glucose metabolism in pregnancy and promotinghealthy growth, body composition and wellbeing in
the offspring.
Trial status
Recruitment for the trial commenced on 3 August 2015;
more than half of the participants have been recruited
within the following 12 months and recruitment remains
ongoing in October 2016. Participants have already pro-
gressed through the randomisation and pregnancy
phases of the study and initial deliveries have occurred
in all three sites.
Additional file
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